Market: NASD |
Currency: USD
Address: 201 Haskins Way
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
📈 CERo Therapeutics Holdings, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$45.00
-
Upside/Downside from Analyst Target:
442.17%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.050000 |
- |
2025-06-13 |
- |
Stock split |
| $0.010000 |
- |
2025-01-08 |
- |
Stock split |
|
Total Amount for 2025: $0.060000 |
📅 Earnings & EPS History for CERo Therapeutics Holdings, Inc.
| Date | Reported EPS |
|---|
| 2025-05-15 | -31.8 |
📰 Related News & Research
No related articles found for "cero therapeutics".
